Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI).
Ewa Mrózek(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Doreen M. Agnese(Saint John's Health Center), Xiao Yang, Rachel M. Layman(The University of Texas MD Anderson Cancer Center), L. A. Houton, Maryam B. Lustberg(Yale Cancer Center), Dimitrios G. Spigos, Stephen P. Povoski(The Ohio State University), B Ramaswamy, Michael V. Knopp(University of California, Los Angeles)
Cited by 13
Related Papers
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
|Neuro-Oncology|2015|670
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
|Nature Reviews Clinical Oncology|2023|296